21.5 C

US drug company commences COVID-19 vaccine trial in South Africa


1min read

AMERICAN vaccine development company Novavax has commenced a Phase 2b COVID-19 clinical trial in South Africa.

The company in a statement signed on Monday by Gregory M. Glenn, president of Research and Development at Novavax stated that the trial will evaluate the efficacy of a COVID-19 vaccine candidate, according to local media.

He stated that Dr Shabir Madhi, a professor of Vaccinology at Wits University, will lead the clinical trial which is supported in part by a $15 million grant from the Bill & Melinda Gates Foundation.

Gleen said, “South Africa is experiencing a winter surge of Covid-19 disease, this important Phase 2b clinical trial has the potential to provide an early indication of efficacy, along with additional safety and immunogenicity data for NVX-CoV2373.”

He also stated that the trial would consist of two cohorts, noting that the first cohort would evaluate efficacy, safety and immunogenicity in approximately 2,665 healthy adults, while second cohort would evaluate safety and immunogenicity in approximately 240 medically stable, HIV-positive adults.

Gleen noted that if the COVID-19 vaccine is approved, it would ultimately be supplied in the country through a recently announced collaboration with the Serum Institute of India.

Madhi, who expressed his excitement and optimism to work as the principal investigator in the clinical trial said COVID-19 vaccine’s positive Phase 1 data will provide strong rationale for moving development forward in a larger subset of adults.

- Advertisement -

“The major motivation for the Covid-19 vaccines being evaluated at an early stage in South Africa is to generate evidence in the African context on how well these vaccines work in settings such as our own,” said Madhi

Gleen, however, appreciated the continued support of the Bill & Melinda Gates Foundation and CEPI, saying that the ongoing collaboration with Wits University will produce and deliver a safe, effective vaccine across the globe.”


'Niyi works with The ICIR as an investigative reporter and fact-checker. You can shoot him an email via [email protected] You can as well follow him on Twitter via @niyi_oyedeji.

- Advertisement -
- Advertisement -
Niyi OYEDEJIhttps://www.icirnigeria.org/
'Niyi works with The ICIR as an investigative reporter and fact-checker. You can shoot him an email via [email protected] You can as well follow him on Twitter via @niyi_oyedeji.


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Support the ICIR

We need your support to produce excellent journalism at all times.


Abia Governor’s Office spends N2.2bn on welfare, N1.4bn on vehicles in a year – Report

A report by The ICIR and The Mail has exposed how Abia State Government,...

Fani-Kayode joins APC, a party he once referred to as Almajiri Peoples Congress

FORMER Minister of Aviation Femi Fani-Kayode has officially joined the All Progressives Congress (APC)...

Southern governors back states’ collection of VAT

THE Southern Governors of Nigeria have resolved to support the collection of value added...

Tax expert urges FG, states to dialogue VAT sharing formula

A TAX expert has urged Nigeria's Federal Government and states to dialogue a value...

EFCC chairman stable after illness at public event

THE Economic and Financial Crime Commission (EFCC) has said its Chairman Abdulrasheed Bawa was...

Most Read


Subscribe to our newsletter